ReviewClinica chimica acta; international journal of clinical chemistry2020
Calprotectin in inflammatory bowel disease.
Review in Clinica chimica acta; international journal of clinical chemistry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 92 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
92 citing papers in PubMed, 3 syntheses or guidelines pooled it, 134 citations in OpenAlex.
- A guideline on biomarkers in the diagnosis and evaluation in axial spondyloarthritis.Frontiers in immunology · 2024Guideline
- A bibliometric and visual analysis of the use of ustekinumab in Crohn's disease using CiteSpace.Frontiers in pharmacology · 2023Pooled it
- The value of fecal calprotectin inFrontiers in physiology · 2022Pooled it
- Precision synbiotic intervention with 2'-fucosyllactose and infant-derivedFrontiers in nutrition · 2026Trial
- Effect of montelukast on remission maintenance in patients with ulcerative colitis: a Randomized, double-blind controlled clinical trial.BMC gastroenterology · 2025Trial
- Prevalence and Lack of Cross-Sectional Association Between Positive Lactulose Breath Test Findings and Fecal Calprotectin Positivity in Patients with Functional Diarrhea.Diagnostics (Basel, Switzerland) · 2026Article
- Analysis of multiplexed SERS-based lateral flow assays: turning qualitative into quantitative for inflammatory bowel disease monitoring.The Analyst · 2026Article
- Bowel Wall Vascularization in Crohn's Disease: Exploratory Comparison of Vendor-Derived Vascular Index, ImageJ-Based Quantification, and Blinded Video-Based Doppler Scoring.Diagnostics (Basel, Switzerland) · 2026Article
- Advancing Predictive Modeling of Inflammatory Bowel Disease (IBD) Flares: A Data-Driven Approach Using Lifestyle and Psychosocial Factors from a Remote Monitoring Platform.Digestive diseases and sciences · 2026Observational
- Review
- Purified Diets Lacking Fermentable Fiber Reduce Microbial Diversity, Alter Epithelial Transcriptome, and Exacerbate Colitis.Nutrients · 2026Article
- Serum Cytokine Profiles Associated with Inflammation and Tumor Progression in Crohn's Disease and Colorectal Cancer.International journal of molecular sciences · 2026Article
- A chemiluminescence assay targeting granzyme A activity for monitoring inflammatory bowel disease.Nature biomedical engineering · 2026Article
- Gut barrier-microbiota crosstalk in sepsis: from pathogenesis to potential therapies.Frontiers in immunology · 2026Review
- S100A8/A9 as a key player in colorectal cancer: from diagnosis to therapeutic targeting.Frontiers in pharmacology · 2026Review
- Hemoglobin-to-Inflammation Marker Ratios Reflect Endoscopic Activity in Inflammatory Bowel Disease.Journal of inflammation research · 2026Article
- Potential Role of Circulating miR-103a, miR-145 and miR-191 as Diagnostic Biomarkers for Ulcerative Colitis and Crohn's Disease.International journal of molecular sciences · 2025Article
- Article
- Development and Validation of a Clinical Decision Support Tool to Predict Disease Progression in Crohn's Disease Treated with Ustekinumab.Journal of clinical medicine · 2025Article
- Salivary Biomarker Profile in Periodontal Diseases: A Cross-Sectional Study on Leptin, Adiponectin, and Calprotectin.Diagnostics (Basel, Switzerland) · 2025Article
32 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The term IBD is usually used for referring to a group of inflammatory gastro-intestinal diseases (mainly Crohn's disease and ulcerative colitis). Accordingly, IBD arises as a result of inappropriate immune response to intestinal commensal organisms among genetically susceptible individuals. Performing colonoscopy and histopathologic evaluation on an inflamed bowel biopsy specimen are currently considered as gold standards for diagnosis and management of IBD. Correspondingly, these techniques are known to be invasive and costly. In recent decades, fecal calprotectin, as a biomarker, has received much attention for the diagnosis and non-invasive management of IBD. Up to now, many studies have investigated the efficacy of fecal calprotectin in the areas of IBD differentiation from IBS, prediction of endoscopic and histologic activities of IBD and prediction of disease recurrence. Although some of these studies have reported promising results, some others have shown significant limitations. Therefore, in this paper, we reviewed the most interesting ones of these studies after a brief discussion of the laboratory measurement of fecal calprotectin. Moreover, we attempted to provide an answer for the question of whether fecal-calprotectin could be considered as a potential surrogate marker for colonoscopy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.